PENTHRANE
LOE ApproachingNDAINHALATIONLIQUIDPriority Review
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENTHRANE (methoxyflurane) is an inhaled volatile liquid anesthetic approved in 1962 for general anesthesia induction and maintenance. As a small-molecule halogenated ether, it works by depressing central nervous system activity to produce unconsciousness. It is primarily used in perioperative anesthesia settings.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams are likely consolidating and focused on cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PENTHRANE offers limited career growth due to zero linked job openings and declining market relevance. Roles are primarily operational and compliance-focused, suited for candidates seeking stable, non-growth-oriented positions in a legacy product environment.
Manufacturing EngineerSupply Chain Manager
Worked on PENTHRANE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.